ABSTRACT OF DISCLOSURE

TABLET FOR ORAL ADMINISTRATION COMPRISING 2-[(4-METHOXY-3-METHYL)-2-PYRIDINYL]METHYLSULFINYL-5-(1H-PYRROL-1-YL)-1H-BENZIMIDAZOLE

The present invention provides an tablet for oral administration prepared by mixing the active ingredient, 2-[(4-methoxy-3-methyl)-2-pyridinyl]methylsulfinyl-5-(1H-pyrrol-1-yl)-1H-benzimidazole, alkali compound as a stabilizer, and a pharmaceutically acceptable additive, tableting the mixture to make a naked tablet, firstly coating the naked tablet with a film forming material, and secondly coating the tablet with an enteric coating material.